240
Participants
Start Date
July 19, 2022
Primary Completion Date
November 28, 2022
Study Completion Date
December 20, 2022
Hydroxymethylquinoxalindioxyde
Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
Chelyabinsk Regional Clinical Dermatology and Venereology Dispensary, Chelyabinsk
Professor Gorbakov Clinic, LLC, Krasnogorsk
Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology of the Moscow Department of Health, Moscow
Federal State Budgetary Educational Institution of Higher Professional Education Ryazan State Medical University, Ministry of Health of Russia, Ryazan
Regional Clinical Dermatology and Venereology Dispensary, Ryazan
City Dermatological and Venereological Dispensary, Saint Petersburg
Northwestern Center for Evidence-based Medicine, JSC, Saint Petersburg
"Private Health Care Institution Clinical Hospital RZD-Medicine of St. Petersburg", Saint Petersburg
Yakusi Clinic, LLC, Saint Petersburg
Clinic of Modern Medicine of Dr. Bogorodskaya, LLC, Yaroslavl
Valenta Pharm JSC
INDUSTRY